Pre-made Moxetumomab biosimilar ( Fv Fusion, anti-CD22 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-358
Anti-CD22 therapeutic antibody (Pre-made Moxetumomab biosimilar,Fv Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Moxetumomab pasudotox-tdfk injection is used to treat hairy cell leukemia that has worsened or cannot be completely removed in patients who have had at least two previous treatments that did not work well.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD22 therapeutic antibody (Pre-made Moxetumomab biosimilar,Fv Fusion)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||National Cancer Institute (USA);AstraZeneca;M. D. Anderson Cancer Center;MedImmune;National Cancer Institute (USA)|
|Conditions Approved||Hairy cell leukaemia|
|Conditions Discontinued||Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma|
|Development Tech||CAT Phage Display|